Endocrine Abstracts

Background: High-specific activity iodine-131 metaiodobenzylguanidine (HSA I-131 MIBG; AZEDRA®) is the only FDA approved systemic treatment for locally advanced or metastatic pheochromocytoma or paraganglioma (PPGL). We have previously described pivotal study efficacy data that served as the basis for HSA I-131 MIBG approval demonstrating improvements in blood pressure control, objective tumor responses, and biomarker responses. Here we provide the results from a European...